Ligand Pharma Dives After Out-Licensed Drug Misses Study Goal

Ligand Pharmaceuticals fell double-digits Tuesday after Amgen said the multiple myeloma therapy Kyprolis, which it licenses from Ligand, failed to show superiority against a rival drug.